-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Neutral on Quest Diagnostics, Raises Price Target to $245

Benzinga·09/08/2026 16:58:30
Listen to the news
UBS analyst Kevin Caliendo maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $232 to $245.